Has The Market Rerated Tarsus Pharmaceuticals (TARS) Too Cautiously After XDEMVY Adoption Headlines? [Yahoo! Finance]
Tarsus Pharmaceuticals, Inc. (TARS)
Company Research
Source: Yahoo! Finance
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. If you are wondering whether Tarsus Pharmaceuticals is still attractively priced after its recent run, this article will walk through what the current share price could imply about value. The stock last closed at US$72.65, with returns of 14.8% over 7 days, 6.9% over 30 days, a 10.1% decline year to date, 70.7% over 1 year and a very large gain over 3 years that is well above 7x. Recent price moves have come alongside heightened attention on the company's lead asset and its potential market, as well as broader discussion around prescription trends and competitive positioning in its treatment area. Together, these news items give important context for why the market is rethinking both the opportunity and the risks. Our Simply Wall St valuation checks currently give Tarsus Pharmaceuticals a value score of 5 out of 6 . Next, we will walk thr
Show less
Read more
Impact Snapshot
Event Time:
TARS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TARS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TARS alerts
High impacting Tarsus Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
TARS
News
- Tarsus Pharmaceuticals (TARS) was downgraded by <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=TARS&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> from MarketBeat
- Tarsus Pharmaceuticals (TARS) was downgraded by Zacks Research from "strong-buy" to "hold".MarketBeat
- Tarsus to Participate in Upcoming Investor ConferencesGlobeNewswire
- Tarsus Pharmaceuticals (TARS) had its price target raised by Oppenheimer Holdings, Inc. from $95.00 to $105.00. They now have an "outperform" rating on the stock.MarketBeat
- Tarsus Pharmaceuticals (TARS) had its price target raised by Guggenheim from $87.00 to $90.00. They now have a "buy" rating on the stock.MarketBeat
TARS
Earnings
- 2/23/26 - Miss
TARS
Sec Filings
- 3/5/26 - Form 4
- 3/4/26 - Form 144
- 2/23/26 - Form S-8
- TARS's page on the SEC website